CN Patent

CN117298114A — 用于治疗hib感染和aids的方案

Assigned to Janssen R&D Ireland ULC · Expires 2023-12-29 · 2y expired

What this patent protects

本发明涉及用于治疗HIB感染和AIDS的方案。治疗HIV的方法，包括每4周一次或更不频繁地肌内给药卡博特韦或其可药用盐和利匹韦林或其可药用盐的组合产品，包括中止第一口服抗逆转录病毒方案的给药并四周一次或更不频繁地肌内给药卡博特韦和利匹韦林的所述组合产品的选择。

USPTO Abstract

本发明涉及用于治疗HIB感染和AIDS的方案。治疗HIV的方法，包括每4周一次或更不频繁地肌内给药卡博特韦或其可药用盐和利匹韦林或其可药用盐的组合产品，包括中止第一口服抗逆转录病毒方案的给药并四周一次或更不频繁地肌内给药卡博特韦和利匹韦林的所述组合产品的选择。

Drugs covered by this patent

Patent Metadata

Patent number
CN117298114A
Jurisdiction
CN
Classification
—
Expires
2023-12-29
Drug substance claim
No
Drug product claim
No
Assignee
Janssen R&D Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.